Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx -: Long-term results

被引:12
|
作者
Kovács, AF
Ghahremani, MT
Stefenilli, U
Bitter, K
机构
[1] Goethe Univ Frankfurt, Sch Med, Clin Maxillofacial Plast Surg, Frankfurt, Germany
[2] Inst Stat, Wurzburg, Germany
关键词
head and neck neoplasms; mouth neoplasms; adjuvant chemotherapy; cisplatin; fluorouracil;
D O I
10.1179/joc.2003.15.5.495
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adjuvant chemotherapy has not yet been proven to have a survival benefit for patients with head and neck cancer. Studies dealing with this topic have had several faults like mingling tumor localizations and treatment modalities. To re-examine the role of postoperative chemotherapy in oral cavity cancer, a single-center study was conducted with the attempt to have higher homogeneity. 122 patients with primary squamous cell carcinoma of the lip, the oral cavity and the oropharynx have been treated with 100 mg/m(2) cisplatin bolus infusion and 120-h continuous infusion of 1000 mg/m(2) 5-fluorouracil following radical surgery; 99 patients completed all 3 cycles. The disease-free and overall survival are reported and compared to a control group of 161 patients with cancer of the lip, the oral cavity and oropharynx treated only with surgery, and a treatment-dependent prognostic index. After a median follow-up of 79 months (range 5-18 years), the current 5-year overall survival of the chemotherapy group was 67% and the 5-year disease-free survival was 57% while the respective data for the control group are 46% and 40%. This difference is statistically significant. The comparison with the prognostic index confirmed this result. The chemotherapy group suffered from fewer local and more neck relapses and had a much longer relapse latency (29 months versus 8 months). The toxicity of the chemotherapy regimen was tolerable. In a homogeneous population with resectable oral cavity and oropharyngeal cancer, postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil resulted in a high overall survival rate which was significantly better than in a comparable population treated only with surgery and better than the survival expectation calculated with the help of a prognostic index. A prospective randomized study of postoperative chemotherapy versus control, exclusively in patients with oral cancer, is warranted.
引用
收藏
页码:495 / 502
页数:8
相关论文
共 50 条
  • [41] Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for metastatic urothelial cancer
    Iwao Fukui
    Junji Yonese
    Tetsuro Tsukamoto
    Tetsuya Yoshida
    Taisei Kim
    Tsuguhiro Tohma
    Daisuke Ishiwata
    Cancer Chemotherapy and Pharmacology, 2001, 48 : 88 - 93
  • [42] Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for metastatic urothelial cancer
    Fukui, I
    Yonese, J
    Tsukamoto, T
    Yoshida, T
    Kim, T
    Tohma, T
    Ishiwata, D
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (01) : 88 - 93
  • [43] CISPLATIN, METHOTREXATE, AND 5-FLUOROURACIL COMBINATION CHEMOTHERAPY FOR ADVANCED OVARIAN-CANCER
    CONTE, PF
    SERTOLI, MR
    BRUZZONE, M
    RUBAGOTTI, A
    ROSSO, R
    BENTIVOGLIO, G
    CONIO, A
    PESCETTO, G
    GYNECOLOGIC ONCOLOGY, 1985, 20 (03) : 290 - 297
  • [44] CISPLATIN AND 5-FLUOROURACIL IN ADVANCED CANCER OF THE PENIS
    SHAMMAS, FV
    OUS, S
    FOSSA, SD
    JOURNAL OF UROLOGY, 1992, 147 (03): : 630 - 632
  • [45] Improved treatment results in rectal cancer by postoperative radiotherapy and 5-fluorouracil
    Tveit, KM
    Guldvog, I
    Hagen, S
    Trondsen, E
    Harbitz, T
    Nygaard, K
    Nilsen, JB
    Wist, E
    Hannisdal, E
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 699 - 699
  • [46] Long-term follow-up in patients treated with curative electrochemotherapy for cancer in the oral cavity and oropharynx
    Landstrom, Fredrik J.
    Reizenstein, Johan
    Adamsson, Gun-Britt
    Von Beckerath, Mathias
    Moller, Claes
    ACTA OTO-LARYNGOLOGICA, 2015, 135 (10) : 1070 - 1078
  • [47] Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study
    Jingu, Keiichi
    Matsushita, Haruo
    Takeda, Ken
    Umezawa, Rei
    Takahashi, Chiaki
    Sugawara, Toshiyuki
    Kubozono, Masaki
    Abe, Keiko
    Tanabe, Takaya
    Shirata, Yuko
    Yamamoto, Takaya
    Ishikawa, Youjirou
    Nemoto, Kenji
    BMC CANCER, 2012, 12
  • [48] LONG-TERM STABILITY OF 5-FLUOROURACIL AND FOLINIC ACID ADMIXTURES
    MILANO, G
    ETIENNE, MC
    CASSUTOVIGUIER, E
    RENEE, N
    BOUSSELET, M
    GUILLOT, T
    LECOMPTE, D
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (01) : 129 - 132
  • [49] Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis
    Noriyuki Nishiwaki
    Kazuhiro Noma
    Tomoyoshi Kunitomo
    Masashi Hashimoto
    Naoaki Maeda
    Shunsuke Tanabe
    Kazufumi Sakurama
    Yasuhiro Shirakawa
    Toshiyoshi Fujiwara
    Esophagus, 2022, 19 : 626 - 638
  • [50] Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis
    Nishiwaki, Noriyuki
    Noma, Kazuhiro
    Kunitomo, Tomoyoshi
    Hashimoto, Masashi
    Maeda, Naoaki
    Tanabe, Shunsuke
    Sakurama, Kazufumi
    Shirakawa, Yasuhiro
    Fujiwara, Toshiyoshi
    ESOPHAGUS, 2022, 19 (04) : 626 - 638